GE Healthcare Launches Cytiva Plus Cardiomyocytes - - BioPharm International

ADVERTISEMENT

GE Healthcare Launches Cytiva Plus Cardiomyocytes


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

GE Healthcare introduces the Cytiva Plus, a high fidelity human heart cell model that is available in quantities compatible with screening for cardiotoxicity, enabling earlier and more confident prioritization of compounds.

The Cytiva Plus is cryopreserved in quantities to match a range of applications, which are ready-for-use in multi-electrode arrays, impedance, and high content analysis applications for compound safety profiling.

The cardiomyocytes are produced in a way that reflects native human heart cell development, without engineering techniques that could alter expression levels of relevant genes. This makes Cytiva Plus a reproducible biologically relevant cell model that supports the measurement of electrophysiological, structural and functional cell changes, and demonstrates expected pharmacological responses to reference compounds, the company reports.

Cytiva Plus is compatible with various detection platforms, enabling compound profiling based on multiple cardiotoxicity indications for more integrated risk assessment and mechanistic investigations.

Source: GE Healthcare

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here